FI20136128L - Pharmaceutical compositions containing josamycin and a method for their preparation - Google Patents

Pharmaceutical compositions containing josamycin and a method for their preparation Download PDF

Info

Publication number
FI20136128L
FI20136128L FI20136128A FI20136128A FI20136128L FI 20136128 L FI20136128 L FI 20136128L FI 20136128 A FI20136128 A FI 20136128A FI 20136128 A FI20136128 A FI 20136128A FI 20136128 L FI20136128 L FI 20136128L
Authority
FI
Finland
Prior art keywords
josamycin
preparation
pharmaceutical compositions
compositions containing
pharmacology
Prior art date
Application number
FI20136128A
Other languages
Finnish (fi)
Swedish (sv)
Inventor
Elena Nikolskaya
Evgeny Vorontsov
Evgenij Severin
Victor Gulenko
Maxim Mitrokhin
Maksim Iurchenko
Original Assignee
Filana Ltd Oy
Unichempharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Filana Ltd Oy, Unichempharm Ltd filed Critical Filana Ltd Oy
Priority to FI20136128A priority Critical patent/FI20136128L/en
Priority to PCT/FI2014/050857 priority patent/WO2015071543A1/en
Publication of FI20136128L publication Critical patent/FI20136128L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The present invention relates to the field of pharmacology and medicine, particularly to an antimicrobial controlled-released drug composition based on josamycin, containing the antibiotic, a copolymer of lactic and glycolic acid, D-mannitol, and polyvinyl alcohol in dimethyl sulfoxide.
FI20136128A 2013-11-15 2013-11-15 Pharmaceutical compositions containing josamycin and a method for their preparation FI20136128L (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20136128A FI20136128L (en) 2013-11-15 2013-11-15 Pharmaceutical compositions containing josamycin and a method for their preparation
PCT/FI2014/050857 WO2015071543A1 (en) 2013-11-15 2014-11-13 Josamycin-based pharmaceutical composition and a process for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20136128A FI20136128L (en) 2013-11-15 2013-11-15 Pharmaceutical compositions containing josamycin and a method for their preparation

Publications (1)

Publication Number Publication Date
FI20136128L true FI20136128L (en) 2015-05-16

Family

ID=53056843

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20136128A FI20136128L (en) 2013-11-15 2013-11-15 Pharmaceutical compositions containing josamycin and a method for their preparation

Country Status (2)

Country Link
FI (1) FI20136128L (en)
WO (1) WO2015071543A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5271489A (en) * 1975-10-31 1977-06-14 Yamanouchi Pharmaceut Co Ltd Synthesis of josamycin derivative
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US8362086B2 (en) * 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
CN101380291A (en) * 2006-08-28 2009-03-11 孔庆忠 Sustained-release injection and preparation method thereof

Also Published As

Publication number Publication date
WO2015071543A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CY1123649T1 (en) IMIDAZOLINE DERIVATIVES, METHODS OF THEIR PREPARATION AND THEIR APPLICATIONS IN MEDICINE
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112017002811A2 (en) pyrrolopyrimidine compounds used as tlr7 agonist
CY1121928T1 (en) PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
NI201500135A (en) PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
NZ712350A (en) Abiraterone acetate formulation
MX2022003458A (en) A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
BR112016012146A2 (en) COMPOUNDS OF AMINOPYRIDINE DERIVATIVES AS KINASE INHIBITORS OF THE TAM FAMILY, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND THERAPEUTIC USE THEREOF
BR112014022214A2 (en) antibacterial phenolics
WO2014144295A8 (en) Ceftolozane antibiotic compositions
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112016001876A2 (en) tricyclic benzoxaborol compound, method of preparation and use thereof
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
AU2017262586A1 (en) Improved drug formulations
CY1117210T1 (en) 2-oxo-1-imidazolidinyl imidazothiadiazole derivative
BR112018007068A2 (en) quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors
BR112017026904A2 (en) lefamulin injectable pharmaceutical formulations
WO2015001163A3 (en) Lipid nanoparticles for healing wounds
MX364652B (en) Pharmaceutical formulation comprising ciclesonide.
MY184630A (en) Tylosin derivatives and method for preparation thereof
MX371209B (en) A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
BR112016029619A8 (en) FLUOROQUINOLONE CLASS COMPOUNDS, PHARMACEUTICAL COMPOSITION AND DRUG COMPRISING SUCH COMPOUNDS AND USES OF SUCH COMPOUNDS
EA201400444A1 (en) DERIVATIVES 2-OXOPYPERIDINYL
EP3435990A4 (en) Stable pharmaceutical compositions for topical administration and uses thereof

Legal Events

Date Code Title Description
FD Application lapsed